Akash Maniam: Personally, the neoadjuvant IO data in early breast cancer is the most intriguing

Akash Maniam, a Medical Oncologist at Portsmouth Hospitals University NHS Trust, and the Clinical Director of Caribbean Cancer Research Institute, shared on LinkedIn:

“Stellar start to ESMO 2023. Personally, the neoadjuvant IO data in early breast cancer is the most intriguing. Increased pCR is fascinating, but does this translate into improved iDFS and OS? Is pCR as meaningful here as in HER2 positive and TNBC cohorts? Is the benefit only confined to PDL1-positive patients? How would adjuvant IO fare in an adjuvant CDK4/6i (and PARPi) world?

So much new data, so many more questions. Look forward to more!”

Source: Akash Maniam/LinkedIn